Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 2 | 4 |
| 1994 | 6 | 4 | 10 |
| 1995 | 11 | 6 | 17 |
| 1996 | 6 | 3 | 9 |
| 1997 | 4 | 5 | 9 |
| 1998 | 2 | 7 | 9 |
| 1999 | 3 | 11 | 14 |
| 2000 | 4 | 7 | 11 |
| 2001 | 10 | 9 | 19 |
| 2002 | 14 | 7 | 21 |
| 2003 | 11 | 12 | 23 |
| 2004 | 18 | 14 | 32 |
| 2005 | 8 | 10 | 18 |
| 2006 | 11 | 14 | 25 |
| 2007 | 15 | 16 | 31 |
| 2008 | 5 | 14 | 19 |
| 2009 | 10 | 10 | 20 |
| 2010 | 7 | 13 | 20 |
| 2011 | 7 | 15 | 22 |
| 2012 | 9 | 18 | 27 |
| 2013 | 11 | 6 | 17 |
| 2014 | 4 | 11 | 15 |
| 2015 | 5 | 13 | 18 |
| 2016 | 2 | 8 | 10 |
| 2017 | 6 | 9 | 15 |
| 2018 | 4 | 8 | 12 |
| 2019 | 3 | 8 | 11 |
| 2020 | 2 | 9 | 11 |
| 2021 | 0 | 8 | 8 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
-
Plasma and cerebrospinal fluid inflammatory markers and human aggression. Neuropsychopharmacology. 2023 06; 48(7):1060-1066.
-
Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.
-
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174.
-
Effects of Vitamin D Supplementation on Adipose Tissue Inflammation and NF-?B/AMPK Activation in Obese Mice Fed a High-Fat Diet. Int J Mol Sci. 2022 Sep 18; 23(18).
-
PUCCINI: Safety of Anti-TNF in the Perioperative Setting. Gastroenterology. 2022 07; 163(1):44-46.
-
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
-
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.